资本事件 | 格瑞农生物 【SynBioCon】 获 悉，近日， 武汉格瑞农生物科技有限公司 （以下简称：格瑞农生物）宣布完成 数千万元Pre-A+轮融资 。 本轮融资主要用于 深化噬菌体多应用场景技术布局，加速公司产品创新、 管线进展、证书申报、市场推广等工作 。 2024年12月，格瑞农生物宣布完成数千万元Pre-A轮融资。 2024年1月，格瑞农生物接连完成天使轮及天使+轮融资，累计募集资金近亿元。 格瑞农生物成立于2019年7月，是一家专注于噬菌体制剂研发与产业化的高新技术企业。 作为全球领先的噬菌体生物制造平台，通过"科研-生产-应用"全产业链布局， 深度赋能智慧养殖、生 态种植、绿色食品、生物医疗四大领域 ，现已成功构建了国际领先的噬菌体库及宿主菌库，为行业提 供了重要的科研支撑和资源平台。 格瑞农生物业务广泛覆盖动物保健（畜禽、水产）、植物保护、食品安全、消费医疗领域，已成功构建 起丰富的产品矩阵：动保领域开发了针对大肠杆菌、沙门氏菌、产气荚膜梭菌、鸭疫里氏杆菌、巴氏杆 菌、波氏杆菌及弧菌等多项噬菌体解决方案，显著降低畜禽细菌性疾病风险；植保领域则推出了推出青 枯病、溃疡病等作物重点病害的速效生 ...

Group 1 - The core viewpoint of the news is that Wuhan Grey Agricultural Biotechnology Co., Ltd. has successfully completed a multi-million yuan Pre-A+ round of financing to enhance its phage application technology and accelerate product innovation and market promotion [1] - The company has raised nearly 100 million yuan in total through various financing rounds since its establishment in July 2019, indicating strong investor confidence and growth potential [1] - Grey Agricultural Biotechnology focuses on phage preparation research and industrialization, establishing itself as a leading global phage manufacturing platform with a comprehensive industry chain layout [1][2] Group 2 - The company has developed a diverse product matrix covering animal health, plant protection, food safety, and consumer healthcare, significantly reducing the risk of bacterial diseases in livestock [2] - The phage therapy approach is gaining traction due to its specificity, environmental friendliness, and low resistance development, positioning it as a strategic avenue in biomedicine and agriculture [6] - The management team is noted for its entrepreneurial spirit and the company's technology platform has been validated across multiple sectors, indicating a strong potential for market expansion [6][7]